ResMed (RMD) Hits A 52-Week High: What's Driving The Stock?
Zacks Investment Research | Dec 16, 2019 08:22PM ET
On Dec 16, shares of ResMed (NYSE:RMD) scaled a new 52-week high of $156.20, closing the session marginally lower at $156. In fact, the stock has rallied nearly 22.5% since its first-quarter fiscal 2020 earnings announcement on Oct 24.
Double-digit global revenue growth in the first quarter, led by strong sales in Software-as-a-Service (SaaS) businesses, launch of mask products and devices as well as robust geographic expansion have prompted the rally.
Let us take a closer look at the factors driving growth.
Robust Q1 Earnings
The fiscal first-quarter revenues in the combined EMEA and APAC region witnessed an 8% rise at CER from the year-earlier tally. A massive 83% surge in global SaaS revenues, driven by continued expansion of Brightree offerings and the MatrixCare buyout, has buoyed optimism.
Gross margin for the quarter was 59.5%, translating into a 115-basis point (bps) expansion from the year-ago number. Adjusted operating margin in the reported quarter rose 115 bps to 27.8%.
Other Encouraging Factors
Investors are optimistic about the company’s recently-inked collaboration deal with Cerner (NASDAQ:CERN) as a new preferred provider for home health and hospice software. This partnership strengthens ResMed’s position as an industry-leading provider of digital health solutions for out-of-hospital healthcare. In fact, ResMed’s MatrixCare team is steadily progressing toward signing a contract with a major healthcare system.
Market is upbeat about ResMed’s expansion of its AirFit mask portfolio with the introduction of its first top-of-head-connected nasal CPAP mask, AirFit N30i, in the United States. The company’s flagship masks, AirFit F20 in the full-face category and AirFit N20 in the nasal category, witnessed solid momentum across global markets in the first quarter of fiscal 2020. The company’s three most recent mask launches, namely, the F30, the N30i and the P30i, have started contributing to the top line significantly. In October 2019, the company launched its latest innovation, N30 — the world’s first ever tube-down nasal cradle CPAP mask in a new product subcategory (which is being called the minimalist category).
Meanwhile, ResMed has been having a great run on the bourses in the past year. The stock has rallied 39.7%, higher than the broader Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.